GenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext Paris

Regulatory News:

THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the availability of a listing prospectus approved by the French Autorité des Marchés Financiers (the "AMF") under number D.24-0299-A01, on May 7, 2024, in the context of the admission to trading on the regulated market of Euronext in Paris of new shares of the Company that will be or may be issued upon (i) a capital increase reserved to specialized investors and (ii) a concurrent capital increase by way of a private placement, by the issuance of new shares with warrants attached, for a total gross amount of approximately €9.2 million.

The listing prospectus approved by the AMF under number D.24-0299-A01 consists of:

• The 2023 universal registration document filed by the Company with the AMF on April 17, 2024 under number D.23-0299;
• The amendment to the 2023 universal registration document filed by the Company with the AMF on May 7, 2024 under number D.24-0299-A01;
• A securities note; and
• The summary of the prospectus (included in the securities note).

These documents are available free of charge on the website of the Company (https://www.gensight-biologics.com) and of the AMF (https://www.amf-france.org).

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage, developed for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.